← Leaderboards
Isla Pearl Garraway
Cedars-Sinai Medical Center
$1,077,887
Attributed
$2,155,774
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $452.4K · FY2021–25$500K$375K$250K$125K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,155,774 · 1
VA$0 · 3
By mechanism
R01$2,155,774 · 1
I01$0 · 3
Top collaborators
- Michael R Freeman5 shared
- Beatrice S Knudsen2 shared
- Anant Madabhushi2 shared
- Kara N Maxwell2 shared
- Nicholas George Nickols2 shared
- Matthew B Rettig2 shared
- Antonio Tito Fojo1 shared
- Saiju Pyarajan1 shared
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Stephen Jay Freedland$7,874,405
- Pao-Hwa Lin$758,037
- Francesca Demichelis$421,824
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Prostate”
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Greg Yothers · University Of Chicago$35,003,821
- Lynn Briscoe · Leidos Biomedical Research, Inc.$30,044,343
- Leonard Freedmand · Leidos Biomedical Research, Inc.$11,639,100
- Himisha Beltran · Dana-Farber Cancer Inst$8,786,271
- John Freymann · Leidos Biomedical Research, Inc.$8,749,308
Research focus
Malignant Neoplasm Of ProstatePrognosticNeoplasm MetastasisCessation Of LifeDiagnosticCohortTissuesNeedle Biopsy ProcedureProstateCastrationGenesReportingResistanceDiagnosisProgramsMetastatic Prostate CancerFamilyExhibitsVariantFundingChromosomal InstabilityBreast Cancer CellAneuploidyAndrogen Receptor
Grant awards (9)
Mechanisms of Prostate Cancer Metastasis$435,646
R01 · FY2025 · CA
Creating precision in metastatic hormone sensitive prostate cancer: Using tumor genetics and patient characteristics to predict outcomes and improve treatment selection$0
I01 · FY2025 · VA
Multi-level factors impacting clinical outcomes in Veterans with low-/intermediate-risk prostate cancer$0
I01 · FY2025 · VA · contact PI
Mechanisms of Prostate Cancer Metastasis$413,864
R01 · FY2024 · CA
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2024 · VA
Mechanisms of Prostate Cancer Metastasis$426,934
R01 · FY2023 · CA
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2023 · VA
Mechanisms of Prostate Cancer Metastasis$426,934
R01 · FY2022 · CA
Mechanisms of Prostate Cancer Metastasis$452,396
R01 · FY2021 · CA